| 1 | relative | 28,877 |
| 2 | low-bias | 20 |
| 3 | chd-equivalent | 3 |
| 4 | health/environmental | 3 |
| 5 | nsaid-attributable | 3 |
| 6 | range=0 | 3 |
| 7 | rosiglitazone-associated | 3 |
| 8 | semicompeting | 3 |
| 9 | value-weighted | 3 |
| 10 | +/-6.2 | 2 |
| 11 | =high | 2 |
| 12 | above-cited | 2 |
| 13 | cholesterol-attributable | 2 |
| 14 | digestor | 2 |
| 15 | duration-specific | 2 |
| 16 | equip-for-quality | 2 |
| 17 | high-anesthetic | 2 |
| 18 | hr/unit | 2 |
| 19 | lifecycle™ | 2 |
| 20 | log-relative | 2 |
| 21 | lousicidal | 2 |
| 22 | low/medium/high | 2 |
| 23 | retative | 2 |
| 24 | socio-familial | 2 |
| 25 | –24 | 2 |
| 26 | 'ultra-high | 1 |
| 27 | -1.162 | 1 |
| 28 | -1.262 | 1 |
| 29 | -115.54 | 1 |
| 30 | -12.54 | 1 |
| 31 | -12.78 | 1 |
| 32 | -15.13 | 1 |
| 33 | -1714.36 | 1 |
| 34 | -181.58 | 1 |
| 35 | -252.73 | 1 |
| 36 | -3.27/-2.84 | 1 |
| 37 | -3.73/-3.33 | 1 |
| 38 | -3.80/-2.72 | 1 |
| 39 | -4.07/-3.24 | 1 |
| 40 | -7.466 | 1 |
| 41 | -70.58 | 1 |
| 42 | -7·4 | 1 |
| 43 | -977 | 1 |
| 44 | -highest | 1 |
| 45 | -€741 | 1 |
| 46 | 1.4-day | 1 |
| 47 | 109.68 | 1 |
| 48 | 118:793-798 | 1 |
| 49 | 15,278 | 1 |
| 50 | 16:343-56 | 1 |
| 51 | 22:176-190 | 1 |
| 52 | 2=in | 1 |
| 53 | 57.3±72 | 1 |
| 54 | 8.57/h | 1 |
| 55 | 9:997-1001 | 1 |
| 56 | anaesthetical | 1 |
| 57 | any-bleeding | 1 |
| 58 | atherosclerotis | 1 |
| 59 | atrialized | 1 |
| 60 | balance/falls | 1 |
| 61 | benefit/ | 1 |
| 62 | between-gender | 1 |
| 63 | bnp-associated | 1 |
| 64 | bulk/surface | 1 |
| 65 | c-similar | 1 |
| 66 | calibrates | 1 |
| 67 | chief-known | 1 |
| 68 | ci:0.0027 | 1 |
| 69 | ci:0.0030 | 1 |
| 70 | ci:0.303 | 1 |
| 71 | ci:0.347 | 1 |
| 72 | ci:0.399 | 1 |
| 73 | ci:0.414 | 1 |
| 74 | ci:0.509 | 1 |
| 75 | ci:0.518 | 1 |
| 76 | ci:0.563 | 1 |
| 77 | ci:0.629 | 1 |
| 78 | ci=-.46 | 1 |
| 79 | ci=-1.55 | 1 |
| 80 | ci=-1.57 | 1 |
| 81 | ci=-4.39 | 1 |
| 82 | ci=-4.70 | 1 |
| 83 | ci=0.35 | 1 |
| 84 | ci=0.54 | 1 |
| 85 | cochrane׳s | 1 |
| 86 | commenest | 1 |
| 87 | common-and-dangerous | 1 |
| 88 | commoncancer | 1 |
| 89 | d-9 | 1 |
| 90 | destination-specific | 1 |
| 91 | drug-splitting | 1 |
| 92 | drug/sex | 1 |
| 93 | epoxy-aza-tricyclic-nonyl | 1 |
| 94 | gastric-cecal | 1 |
| 95 | geometric-phase | 1 |
| 96 | glucocorticoids= | 1 |
| 97 | hematocrit-gfr | 1 |
| 98 | high-added | 1 |
| 99 | income/lower | 1 |
| 100 | intermediate=6 | 1 |
| 101 | letter-digit-letter | 1 |
| 102 | litter-induced | 1 |
| 103 | low-cardiovascular | 1 |
| 104 | low/unclear | 1 |
| 105 | lv+oxaliplatin | 1 |
| 106 | massaging/manipulation | 1 |
| 107 | maxwell-wagner-type | 1 |
| 108 | micro/nano-architectural | 1 |
| 109 | mid-interproximal | 1 |
| 110 | mini-mum | 1 |
| 111 | model’s | 1 |
| 112 | mortality/lethality | 1 |
| 113 | mrd-directed | 1 |
| 114 | ms.cvd | 1 |
| 115 | non-brca-associated | 1 |
| 116 | non-electrostatic | 1 |
| 117 | obesity/lipid | 1 |
| 118 | partner-associated | 1 |
| 119 | patient-tolerance | 1 |
| 120 | post-valdizannian | 1 |
| 121 | profiling-based | 1 |
| 122 | profiling-derived | 1 |
| 123 | programs-a | 1 |
| 124 | psychosocial-environment | 1 |
| 125 | publicly-disseminated | 1 |
| 126 | rare-but-lethal | 1 |
| 127 | rate.our | 1 |
| 128 | re-localized | 1 |
| 129 | season-associated | 1 |
| 130 | ser23 | 1 |
| 131 | sex/hiv | 1 |
| 132 | slow=15 | 1 |
| 133 | smoking.lifestyle-related | 1 |
| 134 | transfusion-specific | 1 |
| 135 | trombophilic | 1 |
| 136 | ukpds-derived | 1 |
| 137 | urethero-vesical | 1 |
| 138 | variant-related | 1 |
| 139 | verbal-paired | 1 |
| 140 | ypn1 | 1 |
| 141 | ypn3a | 1 |
| 142 | −0.22 | 1 |
| 1 | 'ultra-high | 1 |
| 2 | +/-6.2 | 2 |
| 3 | -1.162 | 1 |
| 4 | -1.262 | 1 |
| 5 | -115.54 | 1 |
| 6 | -12.54 | 1 |
| 7 | -12.78 | 1 |
| 8 | -15.13 | 1 |
| 9 | -1714.36 | 1 |
| 10 | -181.58 | 1 |
| 11 | -252.73 | 1 |
| 12 | -3.27/-2.84 | 1 |
| 13 | -3.73/-3.33 | 1 |
| 14 | -3.80/-2.72 | 1 |
| 15 | -4.07/-3.24 | 1 |
| 16 | -7.466 | 1 |
| 17 | -70.58 | 1 |
| 18 | -7·4 | 1 |
| 19 | -977 | 1 |
| 20 | -highest | 1 |
| 21 | -€741 | 1 |
| 22 | 1.4-day | 1 |
| 23 | 109.68 | 1 |
| 24 | 118:793-798 | 1 |
| 25 | 15,278 | 1 |
| 26 | 16:343-56 | 1 |
| 27 | 22:176-190 | 1 |
| 28 | 2=in | 1 |
| 29 | 57.3±72 | 1 |
| 30 | 8.57/h | 1 |
| 31 | 9:997-1001 | 1 |
| 32 | =high | 2 |
| 33 | above-cited | 2 |
| 34 | anaesthetical | 1 |
| 35 | any-bleeding | 1 |
| 36 | atherosclerotis | 1 |
| 37 | atrialized | 1 |
| 38 | balance/falls | 1 |
| 39 | benefit/ | 1 |
| 40 | between-gender | 1 |
| 41 | bnp-associated | 1 |
| 42 | bulk/surface | 1 |
| 43 | c-similar | 1 |
| 44 | calibrates | 1 |
| 45 | chd-equivalent | 3 |
| 46 | chief-known | 1 |
| 47 | cholesterol-attributable | 2 |
| 48 | ci:0.0027 | 1 |
| 49 | ci:0.0030 | 1 |
| 50 | ci:0.303 | 1 |
| 51 | ci:0.347 | 1 |
| 52 | ci:0.399 | 1 |
| 53 | ci:0.414 | 1 |
| 54 | ci:0.509 | 1 |
| 55 | ci:0.518 | 1 |
| 56 | ci:0.563 | 1 |
| 57 | ci:0.629 | 1 |
| 58 | ci=-.46 | 1 |
| 59 | ci=-1.55 | 1 |
| 60 | ci=-1.57 | 1 |
| 61 | ci=-4.39 | 1 |
| 62 | ci=-4.70 | 1 |
| 63 | ci=0.35 | 1 |
| 64 | ci=0.54 | 1 |
| 65 | cochrane׳s | 1 |
| 66 | commenest | 1 |
| 67 | common-and-dangerous | 1 |
| 68 | commoncancer | 1 |
| 69 | d-9 | 1 |
| 70 | destination-specific | 1 |
| 71 | digestor | 2 |
| 72 | drug-splitting | 1 |
| 73 | drug/sex | 1 |
| 74 | duration-specific | 2 |
| 75 | epoxy-aza-tricyclic-nonyl | 1 |
| 76 | equip-for-quality | 2 |
| 77 | gastric-cecal | 1 |
| 78 | geometric-phase | 1 |
| 79 | glucocorticoids= | 1 |
| 80 | health/environmental | 3 |
| 81 | hematocrit-gfr | 1 |
| 82 | high-added | 1 |
| 83 | high-anesthetic | 2 |
| 84 | hr/unit | 2 |
| 85 | income/lower | 1 |
| 86 | intermediate=6 | 1 |
| 87 | letter-digit-letter | 1 |
| 88 | lifecycle™ | 2 |
| 89 | litter-induced | 1 |
| 90 | log-relative | 2 |
| 91 | lousicidal | 2 |
| 92 | low-bias | 20 |
| 93 | low-cardiovascular | 1 |
| 94 | low/medium/high | 2 |
| 95 | low/unclear | 1 |
| 96 | lv+oxaliplatin | 1 |
| 97 | massaging/manipulation | 1 |
| 98 | maxwell-wagner-type | 1 |
| 99 | micro/nano-architectural | 1 |
| 100 | mid-interproximal | 1 |
| 101 | mini-mum | 1 |
| 102 | model’s | 1 |
| 103 | mortality/lethality | 1 |
| 104 | mrd-directed | 1 |
| 105 | ms.cvd | 1 |
| 106 | non-brca-associated | 1 |
| 107 | non-electrostatic | 1 |
| 108 | nsaid-attributable | 3 |
| 109 | obesity/lipid | 1 |
| 110 | partner-associated | 1 |
| 111 | patient-tolerance | 1 |
| 112 | post-valdizannian | 1 |
| 113 | profiling-based | 1 |
| 114 | profiling-derived | 1 |
| 115 | programs-a | 1 |
| 116 | psychosocial-environment | 1 |
| 117 | publicly-disseminated | 1 |
| 118 | range=0 | 3 |
| 119 | rare-but-lethal | 1 |
| 120 | rate.our | 1 |
| 121 | re-localized | 1 |
| 122 | relative | 28,877 |
| 123 | retative | 2 |
| 124 | rosiglitazone-associated | 3 |
| 125 | season-associated | 1 |
| 126 | semicompeting | 3 |
| 127 | ser23 | 1 |
| 128 | sex/hiv | 1 |
| 129 | slow=15 | 1 |
| 130 | smoking.lifestyle-related | 1 |
| 131 | socio-familial | 2 |
| 132 | transfusion-specific | 1 |
| 133 | trombophilic | 1 |
| 134 | ukpds-derived | 1 |
| 135 | urethero-vesical | 1 |
| 136 | value-weighted | 3 |
| 137 | variant-related | 1 |
| 138 | verbal-paired | 1 |
| 139 | ypn1 | 1 |
| 140 | ypn3a | 1 |
| 141 | –24 | 2 |
| 142 | −0.22 | 1 |
| 1 | benefit/ | 1 |
| 2 | ci:0.0030 | 1 |
| 3 | ci=-4.70 | 1 |
| 4 | 22:176-190 | 1 |
| 5 | range=0 | 3 |
| 6 | 9:997-1001 | 1 |
| 7 | -€741 | 1 |
| 8 | ypn1 | 1 |
| 9 | +/-6.2 | 2 |
| 10 | −0.22 | 1 |
| 11 | -1.162 | 1 |
| 12 | -1.262 | 1 |
| 13 | -3.80/-2.72 | 1 |
| 14 | 57.3±72 | 1 |
| 15 | ci:0.303 | 1 |
| 16 | -15.13 | 1 |
| 17 | ser23 | 1 |
| 18 | -3.73/-3.33 | 1 |
| 19 | ci:0.563 | 1 |
| 20 | -252.73 | 1 |
| 21 | ci:0.414 | 1 |
| 22 | -4.07/-3.24 | 1 |
| 23 | –24 | 2 |
| 24 | ci=0.54 | 1 |
| 25 | -12.54 | 1 |
| 26 | -115.54 | 1 |
| 27 | -3.27/-2.84 | 1 |
| 28 | -7·4 | 1 |
| 29 | slow=15 | 1 |
| 30 | ci=0.35 | 1 |
| 31 | ci=-1.55 | 1 |
| 32 | -1714.36 | 1 |
| 33 | ci=-.46 | 1 |
| 34 | 16:343-56 | 1 |
| 35 | -7.466 | 1 |
| 36 | intermediate=6 | 1 |
| 37 | ci:0.0027 | 1 |
| 38 | ci:0.347 | 1 |
| 39 | ci=-1.57 | 1 |
| 40 | -977 | 1 |
| 41 | ci:0.518 | 1 |
| 42 | -70.58 | 1 |
| 43 | -181.58 | 1 |
| 44 | 109.68 | 1 |
| 45 | -12.78 | 1 |
| 46 | 15,278 | 1 |
| 47 | 118:793-798 | 1 |
| 48 | d-9 | 1 |
| 49 | ci:0.509 | 1 |
| 50 | ci:0.629 | 1 |
| 51 | ci=-4.39 | 1 |
| 52 | ci:0.399 | 1 |
| 53 | glucocorticoids= | 1 |
| 54 | programs-a | 1 |
| 55 | ypn3a | 1 |
| 56 | transfusion-specific | 1 |
| 57 | destination-specific | 1 |
| 58 | duration-specific | 2 |
| 59 | trombophilic | 1 |
| 60 | non-electrostatic | 1 |
| 61 | high-anesthetic | 2 |
| 62 | litter-induced | 1 |
| 63 | high-added | 1 |
| 64 | verbal-paired | 1 |
| 65 | profiling-based | 1 |
| 66 | non-brca-associated | 1 |
| 67 | rosiglitazone-associated | 3 |
| 68 | season-associated | 1 |
| 69 | bnp-associated | 1 |
| 70 | partner-associated | 1 |
| 71 | smoking.lifestyle-related | 1 |
| 72 | variant-related | 1 |
| 73 | publicly-disseminated | 1 |
| 74 | mrd-directed | 1 |
| 75 | value-weighted | 3 |
| 76 | above-cited | 2 |
| 77 | profiling-derived | 1 |
| 78 | ukpds-derived | 1 |
| 79 | re-localized | 1 |
| 80 | atrialized | 1 |
| 81 | obesity/lipid | 1 |
| 82 | ms.cvd | 1 |
| 83 | bulk/surface | 1 |
| 84 | patient-tolerance | 1 |
| 85 | nsaid-attributable | 3 |
| 86 | cholesterol-attributable | 2 |
| 87 | maxwell-wagner-type | 1 |
| 88 | geometric-phase | 1 |
| 89 | relative | 28,877 |
| 90 | log-relative | 2 |
| 91 | retative | 2 |
| 92 | any-bleeding | 1 |
| 93 | semicompeting | 3 |
| 94 | drug-splitting | 1 |
| 95 | 8.57/h | 1 |
| 96 | 'ultra-high | 1 |
| 97 | low/medium/high | 2 |
| 98 | =high | 2 |
| 99 | gastric-cecal | 1 |
| 100 | urethero-vesical | 1 |
| 101 | anaesthetical | 1 |
| 102 | lousicidal | 2 |
| 103 | rare-but-lethal | 1 |
| 104 | socio-familial | 2 |
| 105 | mid-interproximal | 1 |
| 106 | micro/nano-architectural | 1 |
| 107 | health/environmental | 3 |
| 108 | epoxy-aza-tricyclic-nonyl | 1 |
| 109 | mini-mum | 1 |
| 110 | post-valdizannian | 1 |
| 111 | 2=in | 1 |
| 112 | lv+oxaliplatin | 1 |
| 113 | massaging/manipulation | 1 |
| 114 | chief-known | 1 |
| 115 | low/unclear | 1 |
| 116 | c-similar | 1 |
| 117 | low-cardiovascular | 1 |
| 118 | commoncancer | 1 |
| 119 | between-gender | 1 |
| 120 | letter-digit-letter | 1 |
| 121 | income/lower | 1 |
| 122 | hematocrit-gfr | 1 |
| 123 | digestor | 2 |
| 124 | rate.our | 1 |
| 125 | low-bias | 20 |
| 126 | calibrates | 1 |
| 127 | atherosclerotis | 1 |
| 128 | balance/falls | 1 |
| 129 | common-and-dangerous | 1 |
| 130 | model’s | 1 |
| 131 | cochrane׳s | 1 |
| 132 | hr/unit | 2 |
| 133 | chd-equivalent | 3 |
| 134 | psychosocial-environment | 1 |
| 135 | -highest | 1 |
| 136 | commenest | 1 |
| 137 | sex/hiv | 1 |
| 138 | drug/sex | 1 |
| 139 | 1.4-day | 1 |
| 140 | mortality/lethality | 1 |
| 141 | equip-for-quality | 2 |
| 142 | lifecycle™ | 2 |